

Special Issue

Humoral and Cellular Response After Vaccination

Message from the Guest Editors

Efficient vaccination relies on inducing a robust adaptive immune response, both cellular and humoral, each playing a specific role in preventing or controlling infection. The challenge in developing an effective vaccine lies in finding the right balance between the different types of immune response required. To evaluate a vaccine, a range of methods have been developed. Immunization markers are constantly evolving, and sometimes newer markers from large data sets, identified through principal component analysis, replace traditional ones. In addition to the polarization of the immune response, the impact of immunization on innate immunity (trained immunity) calls for the use of additional instruments and concepts to assess vaccine effectiveness. This special issue seeks to provide an overview of the current methodology for evaluating vaccines, from the design phase to clinical trials. The proposed articles aim to offer relevant insights into these concepts in the field of modern vaccination.

Guest Editors

Dr. Adrian Onu

1. "Cantacuzino" Institute, 050096 Bucharest, Romania
2. Faculty of Pharmacy, Titu Maiorescu University, 040317 Bucharest, Romania

Dr. Iuliana Caras

Cantacuzino, National Medical-Military Institute for Research and Development, 050096 Bucharest, Romania

Deadline for manuscript submissions

closed (31 October 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/190265

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).